NCT06410300View on ClinicalTrials.gov

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

RecruitingOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

April 19, 2024

Primary Completion Date

April 19, 2028

Study Completion Date

April 19, 2030

Conditions
Lung Cancer
Interventions
RADIATION

Curative Radiotherapy

Radiation dose of 45 Gy or higher

DRUG

Immunotherapy

checkpoint inhibitor per PI discretion

Trial Locations (3)

14642

NOT_YET_RECRUITING

University of Rochester Medical Center, Rochester

65212

RECRUITING

University of Missouri - Ellis Fischel Cancer Center, Columbia

08901

NOT_YET_RECRUITING

Rutgers Cancer Institute of New Jersey, New Brunswick

Sponsors

Lead Sponsor

Bo Lu
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Bo Lu

OTHER

NCT06410300 - Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy | Biotech Hunter | Biotech Hunter